Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs by Li, C. et al.
Regional-Dependent Intestinal Absorption and Meal
Composition Effects on Systemic Availability of LY303366,
a Lipopeptide Antifungal Agent, in Dogs
C. LI,1 D. FLEISHER,1 L. LI,1 J. R. SCHWIER,2 S. A. SWEETANA,2 V. VASUDEVAN,2, L .L. ZORNES,2 L-H. PAO,1†
S. Y. ZHOU,1‡ R. E. STRATFORD2
1 3058 College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065
2 Eli Lilly and Company, Indianapolis, Indiana 46285
Received 7 December 1999; revised 23 August 2000; accepted 24 August 2000
ABSTRACT: Low oral bioavailability and a negative meal effect on drug plasma levels
motivated studies on formulation and meal composition effects on the absorption of
LY303366, a poorly water-soluble, semisynthetic, cyclic peptide antifungal drug. Solid
drug particle size and meal composition studies were evaluated in beagle dogs. Canine
regional absorption studies were also carried out utilizing surgically implanted intes-
tinal access ports, and Caco-2 studies were performed to evaluate drug candidate in-
testinal permeability.
Particle size and Caco-2 data indicate that drug permeability limitations to absorp-
tion are more important than dissolution rate limits. Caco-2 cell-associated LY303366
approached 10% of incubation concentration that is in the range of the oral bioavail-
ability of the drug. Canine regional absorption studies showed that the extent of
LY303366 absorption following duodenal administration was similar to that following
oral administration. Significantly lower drug plasma levels were obtained following
administration through a colonic access port, a result consistent with poor membrane
permeation. Administration of drug with meals of mixed composition, as well as simple
fat and protein meals, resulted in significant reductions in AUC0–48h compared with
results from fasted dogs. In contrast, carbohydrate meals did not reduce drug plasma
levels compared to controls. Intravenous pretreatment with devazepide, a cholecysto-
kinin (CCK) antagonist that blocks canine biliary secretion, did not reverse the nega-
tive effect of the fat meal on LY303366. Taken together, the results from the present
study suggest that membrane-permeability-limited absorption is the cause of the ob-
served regionally dependent absorption of LY303366 in the dog and that the observed
negative meal effects depend on composition but are independent of biliary secretion.
© 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 90:47–57,
2001
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INTRODUCTION
LY303366, a cyclic lipopeptide, is a semisynthetic
analogue of Echinocandin B (ECB) that is being
developed as an antifungal agent. LY303366
shows in vitro and in vivo activity against Can-
dida, Aspergillus,1 and Pneumocystis2 microor-
ganisms. The antifungal potency of LY303366 is
excellent, with a minimum inhibitory concentra-
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tion (MIC) versus C. albicans of 0.005 mg/mL in
vitro. In a mouse model of C. albicans infection,
the ED50 of LY303366, which is the dose at which
50% of animals survive 7 days, was 0.3 and 7.8
mg/kg for intravenous (iv) and oral administra-
tion routes, respectively. The echinocandin lipo-
peptides most likely owe their primary mode of
antifungal activity to their inhibition of the bio-
synthesis of the fungal cell wall.3 LY303366 has a
molecular weight of 1140.3 and is poorly soluble
in water (#0.1 mg/mL), as well as over the pH
range 4–9 (#0.1 mg/mL). It has a log octanol–
water partition coefficient of 2.0. The chemical
structure of LY303366 is shown in Figure 1.
As part of an oral single dose clinical trial
evaluation of LY303366 safety, a negative food
effect (reduced drug plasma levels as compared
with administration with water) was observed.
Specifically, concurrent administration of a 50-
mg dose with a high-fat meal resulted in a 75%
reduction in AUC0–` (area under the curve of con-
centration versus time from time zero to infinity).
Coadministration of a 700-mg dose with a low-fat
meal resulted in a 35% reduction in AUC0–`.
4 In a
preliminary evaluation conducted in dogs, a 30%
decline in both AUC0–` and Cmax (maximum con-
centration) was observed when a 250-mg dose of
LY303366 was coadministrated with a solid
meal.5 At this same dosage, the oral bioavailabil-
ity in dogs administered LY303366 in the fasted
state was ∼5%6 to 10%.7 In this report, formula-
tion studies and Caco-2 permeation studies were
carried out to assess potential rate limits to drug
absorption. Meal composition studies were con-
ducted in dogs to further explore the negative
meal effect. The fact that carbohydrate meals did
not cause a negative effect whereas lipid and pro-
tein meals did result in decreases in LY303366
absorption prompted a limited set of mechanistic
studies to evaluate the impact of inhibition of bil-
iary secretion. When lipid and protein are admin-
istered, the digestion products within the upper
small intestine induce secretion of biliary and
pancreatic fluids that dramatically alter the lu-
minal environment. Bile salts have been reported
to increase the absorption of some hydrophilic
compounds by enhancing the permeability of the
intestinal membrane and some lipophilic com-
pounds by micellar solubilization.8,9 However,
bile salts have also been reported to reduce the
amount of solute in solution available for absorp-
tion of other drugs, which could underlie a nega-
tive food effect with lipid and protein meals.10,11
EXPERIMENTAL SECTION
Materials
14C-LY303366 and 3H-mannitol were from Amer-
sham Life Sciences, Arlington Heights, IL. Eli
Lilly and Company (Indianapolis, IN) supplied
LY303366 parenteral solution (10 mg/ mL).
LY303366 standard compound and its internal
standard (306168, Figure 1) were also from Eli
Lilly and Company. All other materials were com-
mercially available unless stated.
Caco-2 cells were obtained by permission from
the Memorial Sloan-Kettering Cancer Center and
were cultured at 37 °C in a humidified atmo-
sphere of 5% CO2 in air. They were grown in
DMEM:F12 (3:1) media supplemented with 20
mM HEPES, 5% fetal bovine serum, and 50 mg/
mL tobramycin. Monolayers at 75–90% conflu-
ency were either subcultured on a weekly basis,
using a 1:10 split ratio, or seeded onto Millicell-
PCFt polycarbonate inserts (30-mm diameter,
0.4-mm pore size; Millipore Corp., Bedford, MA),
at a density of 600,000 cells per filter, and fed
every other day. For transport studies, cells from
passages 40–42 were used following 21–30 days
post-seeding. Transepithelial electrical resistance
Figure 1. Chemical structure of LY303366 and its
internal standard.
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(TEER) was measured immediately prior to an
experiment using the Millicell-ERS system (Mil-
lipore Corp.). Cells with a net resistance < 300
V ? cm2 were not used.
The reference dexamethasone permeability in
this system was determined under the following
experimental conditions. Initial donor dexameth-
asone concentration was 25 mM traced with 0.5
mCi/mL 3H-dexamethasone. Cold stock solutions
were made up at 2.5 mM with dimethylsulfoxide
(DMSO) so that the final DMSO concentration in
the donor compartment was 1%. Initial dexa-
methasone flux was determined over 180 min,
providing sink conditions, and the receiver com-
partment was sampled at 30-min intervals.
Animal Studies
Studies in dogs adhered to the “Principles of
Laboratory Animal Care” in accordance with NIH
publication #85-23 and were approved by the Uni-
versity Committee on Use and Care of Animals.
Formulation Effects in Fasted Dogs
Using a non-crossover design, 4 fasted beagle
dogs were administered a 250-mg (2 × 125-mg
capsules) dose containing LY303366 with a mean
particle size of either 11 or 154 mm. Then, 50 mL
of water was coadministered with the capsules.
The 11-mm particle sized material was produced
from the larger particle size using a standard al-
pine mill. Blood samples were taken up to 48 h
after administration of drug.
Particle Size Determination
Equivalent spherical volume diameters were
measured using a Horiba LA910 Laser Scattering
Particle Size Distribution Analyzer. Solid drug
sample was suspended in 180 mL of dispersant
solution. Solid sample was added to the disper-
sant until an acceptable level of laser light obscu-
ration was achieved, at which point the particle
size distribution was measured. Prior to the
sample suspension, the dispersant solution was
prepared using 0.1% (w/v) SPAN 80 in cyclohex-
ane. After presaturation with the drug substance,
the dispersant solution was filtered through a 0.2-
mm microporous membrane filter to provide the
necessary particle-free suspending dispersant.
The 154-mm (mean) drug sample showed 90%
particles cumulatively <315 mms (d90) and 10%
cumulatively <17 mms (d10). The 11-mm (mean)
drug sample showed 90% <19 mms (d90) and 10%
<4 mms (d10). Although a standard deviation was
not obtained, the graphical distributions clearly
represented two different particle size popula-
tions. Additionally, the 154-mm (mean) sample
showed a BET (Brunauer–Emmett–Teller) sur-
face area of 0.44 m2/g, whereas the 11-mm (mean)
sample showed a BET surface area of 2.0 m2/g.
In Vitro Dissolution Studies
Capsule dissolution was reported using the aver-
age of six capsules run via a modified USP paddle
method (paddle speed of 100 rpm) in 900 mL of
1.0% (w/v) polysorbate 80 in purified water main-
tained at 37 °C. Each capsule contained 125 mg of
LY303366. Analysis was conducted using re-
versed-phase high-performance liquid chroma-
tography (HPLC) with ultraviolet (UV) detection
(220 nm). The surfactant was necessary to solu-
bilize sufficient amounts of the active pharmaceu-
tical ingredient.
Caco-2 Permeability Studies
Measurements of transepithelial fluxes of 14C-
LY303366 and 3H-mannitol were made simulta-
neously at 37 ° C using a side-by-side diffusion
chamber described previously.12 The transport
medium consisted of 25 mM HEPES buffer, pH
7.4, along with 125 mM NaCl, 5.2 mM KCl, 1.2
mM CaCl2, 1.2 mM MgCl2, 10 mM glucose, and
0.1% bovine serum albumin. To initiate an experi-
ment, 200 mL of a stock solution of LY303366 and
mannitol in 10% water/90% ethanol was added to
either the apical (14 mL final volume) or basal (13
mL final volume) side of the monolayer. The final
concentration of ethanol was 1.3% (v/v). Samples
(200 mL) were taken from the contralateral com-
partment at various times up to 120 min and re-
placed with an equal volume of fresh transport
buffer. At the beginning and end of an experi-
ment, samples were taken from the donor cham-
ber to determine permeability and mass balance,
respectively. Rates of transport under initial rate
conditions (<10% transport) were determined by
linear regression analysis; these rates were di-
vided by the initial donor concentration to calcu-
late the corresponding permeability coefficients.
Preliminary studies designed to assess the stabil-
ity of LY303366 when subjected to the incubation
conditions just described indicated an LY303366
recovery of $95% between the concentrations of 1
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to 6 mM. The concentration range evaluated was
limited by the solubility of LY303366.
At the conclusion of an incubation, filters were
removed, washed twice with 2 mL of cold pH 7.4
transport buffer, and subsequently transferred
to10 mL of liquid scintillation cocktail for the de-
termination of bound radioactivity. Mass balance
was calculated by dividing the sum of (1) cell as-
sociated radioactivity, (2) the cumulative amount
of radioactivity transported over the duration of
the incubation, and (3) the final donor radioactiv-
ity by the initial donor chamber radioactivity. For
LY303366, mass balance was on average 91 ±
5.3%; average mannitol mass balance was 93 ±
5.4% (n 4 29).
Regional-Dependent Studies
Bolus oral and colonic administration of 25 mL of
LY303366 solution (250-mg dose) was carried out
in four male Beagle Dogs, weighing 9.5–13.6 kg,
utilizing a non-crossover design. Duodenal and
mid-jejunal bolus administration of the same dose
and volume were also conducted in three dogs and
one dog, respectively. Upper and lower intestinal
access ports (Access Technologies, Skokie, IL)
were surgically implanted. The washout period
between each study was at least 1 week. In the
oral study, LY303366 solution was administrated
directly into the stomach through a gastric tube.
In the regional study, drug solution was pushed
as a bolus administration through an intestinal
access port either directly into the small intestine
or colon. Blood samples were taken up to 48 h
after administration of drug.
Meal Effect Studies
Meal effect and subsequent mechanistic studies
were carried out utilizing a non-crossover design.
Fasted and hyper-osmolal solution treatment con-
trols consisted of 250 mg of drug coadministered
with 240 mL of either water or sodium chloride
solution (290 ± 20 mOsm/kg), respectively. Test
meals included a liquid mixed-composition meal
(Ensuret, 250 kcal/240 mL), and fat (20% In-
tralipidt), protein (CASECt Calcium Caseinate),
sucrose, and maltodextrin (Moducalt) meals,
which are all commercially available. Each meal
was prepared to have a final total volume of 240
mL and meal osmolality was adjusted to 480 ± 20
mOsm/kg with NaCl when needed. The total calo-
ries were 250 kcal for Ensuret and Intralipidt
meals, and 125 kcal for protein, sucrose, and
maltodextrin meals. The selection of a lower calo-
rie protein meal compared with the higher calorie
mixed and lipid meals was motivated by a desire
to study low viscosity liquid meals. Following an
overnight fast, LY303366 mixed with control so-
lutions or meal treatments was administrated di-
rectly into the stomach through a gastric tube
within a period of 2–3 min. Blood samples were
drawn up to 48 h after dosing.
Mechanistic Studies
Based on the results from the meal effect studies,
a cholecystokinin (CCK) A-receptor antagonist,
devazepide (ML Laboratories PLC, Wavertree
Technology Park, Liverpool L13 1EN, England),
was utilized to block Intralipidt-stimulated bili-
ary secretion in three dogs. Devazepide was dis-
solved in 1% (w/v) polysorbate 80, 70% (w/v) poly-
ethylene glycol 400, and adjusted to final volume
with 30% (v/v) alcohol to yield a final concentra-
tion of 2 mg/mL. Devazepide (0.1 mg/kg) was in-
fused iv over a 5-min period prior to LY303366
coadministration with the 250 kcal/240 mL In-
tralipidt meal. This devazepide dose totally
blocks oleate-stimulated gallbladder contraction
and biliary secretion in dogs.13
Sample Analysis
Plasma concentrations of LY303366 were mea-
sured using HPLC–UV according to a method de-
scribed previously.14 Briefly, plasma samples
were extracted on an IST 20-position manifold us-
ing a Bond Elut phenyl (PH) SPE column. The
chromatographic conditions were as follows: col-
umn, Zorbax SB-C8 (4.6 × 250 mm, 5-mm particle
size) analytical column with an in-line 2-mm fil-
ter; mobile phase, 45% acetonitrile and 55% 50
mM ammonium phosphate (pH 4.5) buffer; flow
rate, 1.0 mL/min; temperature, 30 °C; and detec-
tion absorbance at 300 nm. LY306168 was used
as the internal standard. The linear range of the
assay was 20–5000 ng/mL. Based on analysis of
control samples prepared at 20, 600, and 5,000
ng/mL, interday accuracy and precision were
91.1–114.1 and 0.6–4.0%, respectively. Intraday
accuracy and precision were 90.2–99.5 and 5.1–
6.3%, respectively. When stored at −70 °C,
LY303366 in dog plasma is stable >5 months.
Data Statistical Analysis
A paired t test was used for all data treatment
unless otherwise stated.
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RESULTS
Formulation Effects in Fasted Dogs
Despite the positive influence of increased surface
area (reduced particle size) on the in vitro disso-
lution rate of LY303366 capsules, as shown in
Figure 2, such increase did not translate to an
improvement in LY303366 systemic absorption in
fasted dogs. Mean (±1 standard error (SE))
AUC0–` was 23.7 ± 3.64 mg ? h/mL following ad-
ministration of a 250-mg dose prepared using
LY303366 bulk of 154 mm mean particle size. This
result was not different (p > 0.05) than the value
of 16.9 ± 2.67 mg ? h/mL obtained following the
same dose prepared using the bulk material with
an average particle size of 11 mms. There was also
no effect of particle size on Cmax, Tmax (time to
reach Cmax) and terminal half-life. These results
suggest that dissolution does not represent the
rate-determining step in the process of LY303366
systemic absorption.
Caco-2 Permeability
Figure 3 is a summary of LY303366 permeability
following either apical or basolateral exposure of
monolayers for 120 min. LY303366 permeability
in the absorptive direction was independent of do-
nor concentration and averaged 3.5 ± 1.10 × 10−6
cm/s (n 4 12). The permeability of 100 mM man-
nitol in this direction was 1.9 ± 0.37 × 10−6 cm/s
(n 4 12), which was significantly less than
Figure 2. Dissolution profile of capsules containing 125 mg of LY303366 with an
average particle size of either (j) 11 mm or (h) 154 mm. Dissolution testing was carried
out in a standard Type 1 dissolution apparatus (100 rpm /paddle) using 900 mL of water
containing 1% Tween 80. The two formulations were tested three times; error bars
represent one SD.
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LY303366 permeability (p 4 0.0002). In the se-
cretory direction, LY303366 permeability was
also independent of concentration, but was ∼2
times greater than permeability in the absorptive
direction (p < 0.0001, one-way analysis of vari-
ance (ANOVA)), with an average permeability of
6.8 ± 0.95 × 10−6 cm/s. Mannitol permeability was
1.9 ±0.42 (n 4 11) in the secretory direction. Al-
though significantly different, mannitol and
LY303366 absorptive permeabilities were only
∼10–15% of dexamethasone permeability, 23.7 ±
0.60 ×10−6 cm/s, which is well absorbed (>75%) in
humans. Both LY303366 and dexamethasone15
have measured log octanol–water partition coef-
ficients of 2.0.
At 120 min, cell-associated LY303366 was in-
dependent of donor concentration but accounted
for 7.3 ± 1.21 and 13.5 ± 0.83% of the total amount
of LY303366 initially present for the absorptive
and secretory transport directions, respectively.
In contrast, cell-associated mannitol was inde-
pendent of transport direction and, at 0.08
±0.020%, was substantially less than LY303366
binding.
Regional-Dependent Absorption
The extent of LY303366 absorption following duo-
denal administration was similar to that follow-
ing oral administration. However, significantly
lower drug plasma levels were obtained following
administration through the colonic access port
(Figure 4). Both AUC 0–48h and Cmax from colonic
administration were significantly decreased (p <
0.05) when compared with oral fasted administra-
tion of LY303366. Administration of LY303366
through a mid-jejunal intestinal access port in
one dog resulted in a substantial decrease in drug
plasma levels compared with oral and duodenal
administration. Regional AUC0–48h values were
23.3, 26.5, 17.7, and 6.9 mg ? h/mL and Cmax 1.6,
1.5, 0.6, and 0.3 mg/mL from oral, duodenal, jeju-
nal, and colonic administration, respectively, in
this dog.
Meal Effect Studies
The contributions of meal osmolality versus ca-
loric density to reduction in drug plasma levels
were studied by comparing the influence of a 480-
mOsm/kg noncaloric saline meal with a control
saline (290 mOsm/kg) drug administration and a
mixed meal (480 mOsm/kg, 250 kcal) treatment.
As shown in Figure 5, absorption of LY303366
was not affected by noncaloric meal hyperosmo-
lality (p 4 0.35). A significant decrease in drug
plasma levels was observed with coadministra-
tion of the 250-kcal, hyperosmolar liquid nutrient
meal of mixed caloric composition. Furthermore,
both an Intralipidt meal of equivalent caloric
density and a reduced calorie protein meal (125
kcal) also resulted in depressed LY303366 plasma
levels compared with drug coadministration with
saline in fasted dogs (Figure 6, Table 1).
Figure 3. Ly303366 permeability coefficients follow-
ing wither (j) apical or (h) basolateral exposure to
three concentrations of LY303366. Values are mean
±SD; n 4 3–6 filters for each concentration. Figure 4. Mean ± SD plasma concentration profiles
of LY303366 following oral and regional administration
in three dogs.
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In contrast to the negative meal effect observed
with either a mixed meal, a lipid meal, or a pro-
tein meal, coadministration of LY303366 with a
125-kcal carbohydrate (either sucrose or Modu-
calt) meal did not decrease drug plasma levels
(Figure 6). In fact, a trend toward increasing
LY303366 levels was indicated by the AUC and
Cmax data, although these values were not signifi-
cantly different than controls. It is also notewor-
thy that meal treatments did not increase
LY303366 plasma level Tmax, which averaged 6.0
h for all treatments including the fasted-state
controls.
Mechanistic Study
As shown in Figure 7, pretreatment of three dogs
with devazepide failed to reverse the reduction
of LY303366 plasma levels observed with In-
tralipidt.
DISCUSSION
LY303366 possesses a low aqueous solubility and
a high octanol–water partition coefficient. How-
ever, an increase in dissolution rate (Figure 2) did
not lead to an increase in systemic absorption.
Furthermore, lipophilic drugs typically provide
for good colonic absorption as demonstrated in a
canine colonic absorption model.16 This behavior
is not observed with LY303366 (Figure 4) in the
same canine colonic access port model. These in
vitro and in vivo studies suggest that the intesti-
nal absorption of LY303366 is not strictly disso-
lution-rate limited.
The low LY303366 absorptive permeability in
human intestinal cell monolayers suggested that
in vivo absorption of LY303366 might be limited
by membrane permeability. Whereas LY303366
has a lipophilic side chain, the polyhydroxyl
structure of the ECB nucleus promotes hydrogen
bonding and likely limits membrane permea-
tion.17 If permeability plays a role in limiting the
absorption of LY303366, it is not surprising that
exposure of the drug to less absorbing surface
area with jejunal and colonic administration pro-
vides lower plasma levels than when the drug
sees more absorbing intestinal surface with oral
or duodenal administration (Figure 4).
As shown in directional transport studies in
human colon cell monolayers (Figure 3), intesti-
nal secretion, possibly mediated by P-glyco-
protein, was observed. Secretory flux of LY303366
was twofold higher compared with absorptive
flux. It has been reported that antifungal resis-
tance to ECB analogs is partially mediated by
Figure 6. Mean ± SD plasma concentration profiles
of LY303366 after oral administration to fasted dogs, or
following LY303366 coadministration with Intralipidt,
protein, or carbohydrate (sucrose and Moducalt) meals.
Figure 5. Mean ± SD plasma concentration profiles
of LY303366 after oral administration to fasted dogs, or
following LY303366 coadministration with either a
mixed liquid nutrient or a noncaloric high osmolality
NaCl solution.
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membrane proteins encoded by MDR-like
genes.18 However, the contribution of an intesti-
nal region-specific drug secretion effect to the ob-
served regional dependence in LY303366 absorp-
tion is unknown because of the multiplicity of se-
cretory transporters and lack of understanding
regarding their distribution in this tissue. In ad-
dition to demonstrating a net secretion of
LY303366, Caco-2 experiments also revealed sub-
stantial binding of LY303366 to the human colon
cell monolayers. In fact, the percent bound is in
the range of the oral bioavailability. This exten-
sive binding might be expected to prolong intes-
tinal residence time and drug availability for ab-
sorption, which might, in turn, contribute the
prolonged oral absorption of LY303366 (Tmax, 6
h). Poor and prolonged absorption behavior has
also been reported for the antifungal, amphoteri-
cin B, a drug with high hydrogen bonding poten-
tial and oral bioavailability and Tmax similar to
that of LY303366.19
In a preliminary canine study, a single 5-mg/kg
oral administration of LY303366 provided drug
plasma levels above the MIC for C. albicans over
a 20-h period and for Aspergillus fumigatus over a
10-h period. However, when the same dose was
coadministered with a solid dog food meal, drug
plasma levels dropped below the MIC for A. fu-
migatus (data not shown). In a follow-up evalua-
tion conducted in dogs, a 30% decline in both
AUC0–` and Cmax was observed when a 250-mg
dose of LY303366 was coadministrated with a
solid meal.20 As part of an oral, single-dose clini-
cal trial evaluation of LY303366 safety, a nega-
tive food effect was also observed. Specifically,
concurrent administration of a 50-mg dose with a
high-fat meal resulted in a 75% reduction in
AUC0–`. Coadministration of a 700-mg dose with
a low-fat meal resulted in a 35% reduction in
AUC0–`.
4 In this study, the influence of meal vol-
ume and composition was further explored in
dogs.
A negative meal effect on drug plasma levels
can be generated when the volume between
fasted- and fed-state treatments is not kept con-
stant. It is often the case in meal effect studies
that only a small volume of fluid is administered
when drug is given in the fasted state, whereas a
large meal volume is given with the drug in fed-
state study treatments. The larger volume serves
to dilute the drug concentration exposed to ab-
sorbing membranes as well as to alter the gastric
emptying time of drug into the small intestine.25
Only 25 mL of water was orally coadministered
with the drug in the regional-dependence studies,
50 mL in the drug particle size studies, and 240
mL of water or saline in the meal effect control
studies. The drug plasma level data in Table 1
and Figures 4, 5, and 6 suggest that a dilution
effect resulting from differences in coadminis-
tered volume does not influence drug plasma lev-
Figure 7. Mean ± SD plasma concentration profiles
of LY303366 after oral administration to fasted dogs, or
following LY303366 coadministration with either In-
tralipidt or Intralipidt with devazepide pretreatment.
Table 1. Comparison of Effects of Meal Treatments on LY303366 Plasma Level Pharmacokinetic Parameters
following Oral Administration of a 250-mg Dose to Dogs
Parameter Fasted Mixed Meal Lipid Meal Protein Meal Carbohydrate Meals
AUC0–48 (mg ? h/mL) 21.2 ± 5.84 8.9 ± 2.56* 7.5 ± 1.84* 8.9 ± 2.77* 25.2 ± 5.13
Cmax (mg/mL) 1.1 ± 0.27 0.5 ± 0.17* 0.4 ± 0.13* 0.5 ± 0.20* 1.6 ± 0.30
a Results are expressed as mean ± SE; Tmax averaged 6.0 h for all treatments; administered volumes are five times higher than
those used in the particle size study; *paired t-test p value # 0.05 relative to fasted conditions.
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els in the fasted state to account for meal effect
observations.
Because the drug does show some instability at
acidic pH, the fact that a meal would prolong gas-
tric residence time might also be considered to
play a role in a negative meal effect. However,
similar drug plasma levels are observed following
oral and duodenal administration. Oral drug ad-
ministration with a noncaloric hyperosmolar so-
lution, which also prolongs gastric residence time
compared with iso-osmolar solutions, also did not
lead to plasma level reduction and lends further
support to the conclusion that acid instability is
not a limiting factor in LY303366 absorption.
In previous clinical studies,4 it was observed
that a negative meal effect could be diminished by
reducing caloric and fat content and by increasing
the drug dose. In the canine meal composition
studies, both lipid and protein meals with differ-
ent caloric density resulted in a similar decrease
in LY303366 absorption (Figure 6). In contrast,
carbohydrate meals did not cause negative meal
effects but rather showed a trend toward increas-
ing drug plasma levels, though this effect was not
statistically significant (Table 1).
Another possible cause of the observed nega-
tive food effect is the influence of meal viscosity
and/or drug binding to meal components. These
factors are particularly important when a signifi-
cant fraction of the drug is absorbed in the upper
intestine, as is the case with LY303366 (Figure 4).
Under fed-state conditions, meal viscosity and
drug binding potential is greatest in the upper
intestine where digestion is at its least complete
stage and will serve to reduce the amount of drug
that gets to the intestinal absorbing surface. In
previous studies in the same dog model with an-
other compound, bidisomide, solid meals were
shown to produce a significant negative meal ef-
fect on drug plasma levels, whereas equivalent
caloric liquid meals of relatively low viscosity did
not. The negative meal effect on bidisomide,
which also showed better absorption in the upper
than lower intestine, was generated by viscous
zero calorie meals.22 Bidisomide binding to meal
components was shown not to underlie the nega-
tive meal effect in equilibrium dialysis experi-
ments.
In a preliminary study, LY303366 was coad-
ministrated with a solid meal, and drug absorp-
tion was observed to decrease by 30% compared
with fasted control studies.5 However, the depres-
sion of LY303366 plasma levels observed upon its
coadministration with a mixed composition liquid
meal of low viscosity (Figure 5) was equivalent to
that observed with the solid meal coadministra-
tion. This result suggests that meal viscosity is
not a significant factor in reducing the absorption
of LY303366. The possibility that LY303366
binds to Intralipidt and Casect but not to sucrose
or Moducalt has not been ruled out in this study.
Because the drug is a lipopeptide, such a selective
interaction is certainly a possibility and could un-
derlie the negative food effect in the case of lipid
and protein. However, on the basis of hydrogen
binding potential, it might be projected that
LY303366 would interact most readily with sug-
ars and polysaccharides.
Another consideration for the difference in ef-
fects on LY303366 absorption as a function of
meal composition is that fat and protein meals
stimulate biliary secretion whereas carbohy-
drates do not. Bile-salt-mediated micellar solubi-
lization of poorly water-soluble compounds may
decrease the intermicellar “free” fraction of drug
in the upper intestine, which in turn could lead to
a decrease in drug absorption.23 In vitro studies
have shown that devazepide is an effective inhibi-
tor of CCK binding to CCK-A receptors in the
pancreas (IC50, 81 pM) and gallbladder (IC50, 45
pM).11 In a study originally carried out at Merck,
Sharp and Dohme Research Laboratories, it was
observed that devazepide completely blocked ole-
ate-stimulated biliary secretion in bile-duct can-
nulated dogs.24 Human studies have also shown
that 10 mg of devazepide is orally active, and com-
pletely inhibits meal-induced gallbladder contrac-
tion with no effect on gastric-emptying.25 Previ-
ous studies in our laboratory have shown that
blockade of lipid-stimulated biliary secretion with
devazepide pretreatment nullified a meal effect in
connection with the absorption of phenytoin.26
However, in the present study, pretreatment with
devazepide failed to reverse the negative meal ef-
fect when LY303366 was coadministrated with
Intralipidt (Figure 7). Based on these results, it
appears that biliary secretion is not likely to be
responsible for the observed negative influence of
lipid- and protein-containing meals on LY303366
absorption. In contrast, lipid–bile salt mixed mi-
celles have been shown to enhance the gastroin-
testinal absorption of amphotericin-B.27
In summary, although initial physicochemical
LY303366 data suggested that low oral bioavail-
ability might be the result of low aqueous solubil-
ity and a dissolution-rate limit to drug absorp-
tion, drug formulation and intestinal permeabil-
ity studies point toward a permeability limitation
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for absorption. Thus, LY303366 might be re-
garded as a Class IV (low solubility — low perme-
ability) drug in accordance with the Biopharma-
ceutical Classification System.28 Coadministra-
tion of meals with LY303366 leads to a reduction
in drug plasma levels in both dogs and humans
compared with administration without food. The
meal effect is composition dependent in that lipid
and protein meals decrease drug plasma levels
whereas carbohydrate meals do not. Caco-2 ex-
periments suggest that the prolonged absorption
profile for LY303366 may be the result of drug
adherence to intestinal membranes. However,
there is no direct evidence for this suggestion, and
the mechanism underlying the negative meal ef-
fect has not been resolved at this time.
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